A closed loop method and apparatus for controlling the administration of an hypnotic drug to a patient. Electroencephalographic (EEG) signal data is obtained from the patient. At least one measure of the complexity of the EEG signal data is derived from the data. The complexity measure may comprise the entropy of the EEG signal data. The EEG signal data complexity measure is used as the feedback signal in a control loop for an anesthetic delivery unit to control hypnotic drug administration to the patient in a manner that provides the desired hypnotic level in the patient. An EEG signal complexity measure obtained from the cerebral activity of the patient can be advantageously used in conjunction with a measure of patient electromyographic (emg) activity to improve the response time of hypnotic level determination and of the feedback control of drug administration. A pharmacological transfer function may be used, along with pharmacokinetic and pharmacodynamic models.
|
1. A method for administering an hypnotic drug to a patient to establish a desired hypnotic level in the patient, said method comprising the steps of:
(a) establishing a reference signal corresponding to the desired hypnotic level to be provided established in the patient from the administration of the hypnotic drug;
(b) administering the hypnotic drug to the patient;
(c) obtaining EEG signal data resulting from cerebral activity of the patient and obtaining emg signals resulting from muscle activity of the patient;
(d) deriving at least one measure of the complexity characteristics of the EEG signal data;
(e) deriving a measure of patient emg activity;
(f) determining the hypnotic level existing in the patient from the complexity characteristics of the EEG signal data combined with the derived measure of patient emg activity and providing a feedback signal corresponding to the hypnotic level existing in the patient;
(f) (g) comparing the feedback signal corresponding to the hypnotic level existing in the patient as a result of the administration of the hypnotic drug to the reference signal corresponding to the desired hypnotic level to be established in the patient from the administration of the drug to produce a control signal, indicative of the difference between the desired hypnotic level and the existing hypnotic level; and
(g) (h) controlling the administration amount of the hypnotic drug administered to the patient in accordance with the comparison of step (f) control signal so that the hypnotic level of the patient is established and maintained at that corresponding to the reference signal.
28. Apparatus for administering an hypnotic drug to a patient to establish a desired hypnotic level in the patient, said apparatus comprising:
(a) means for establishing a reference signal corresponding to a the desired hypnotic level for to be established in the patient from the administration of the hypnotic drug;
(b) an anesthetic delivery unit for administering the hypnotic drug to the patient;
(c) a sensor means for obtaining EEG signal data resulting from the cerebral activity of the patient and for obtaining an emg signal resulting from muscle activity of the patient;
(d) means coupled to said sensor means for deriving at least one measure of the complexity characteristics of the EEG signal data and for deriving a measure of emg activity from the emg signal, for determining the hypnotic level existing in the patient from the complexity characteristics of the EEG signal data combined with the derived measure of emg activity, and for providing a feedback signal corresponding to same the hypnotic level existing in the patient; and
(e) a control unit including a comparator having inputs coupled to said elements (a) and (c) (d) and an output coupled to element (b), said comparator comparing the signals feedback signal corresponding to the hypnotic level existing in the patient as a result of the administration of the hypnotic drug and the reference signal corresponding to the desired hypnotic level to be established in the patient from the administration of the drug and providing an output signal to the anesthetic delivery unit, indicative of the difference between the reference and feedback signals, for controlling the anesthetic delivery unit and the administration amount of the hypnotic drug administered to the patient by the anesthetic delivery unit in accordance with the comparison output signal so that the hypnotic level of the patient is established and maintained at that corresponding to the reference signal.
2. The method according to
3. The method according to
4. The method according to
5. The method according to
6. The method according to
7. The method according to
0. 8. The method according to
0. 9. The method according to
10. The method according to claim 9 1 wherein the step of deriving the measure of patient emg activity is further defined as deriving the measure from a frequency domain power spectrum of the emg signals.
11. The method according to claim 8 1 wherein step (c) is further defined as obtaining emg signals resulting from the muscle activity of the patient and step (d) further includes the step of deriving a measure of the complexity characteristics of EEG signal data over a frequency spectrum incorporating the EEG signals and emg signals for use with the a derived measure of the EEG signal data complexity in controlling the administration of the hypnotic drug to the patient characteristics.
12. The method according to
13. The method according to
14. The method according to
15. The method according to
16. The method according to
17. The method according to
18. The method according to
19. The method according to
20. The method according to
21. The method according to
22. The method according to
23. The method according to
24. The method according to
25. The method according to
26. The method according to
27. The method according to
29. The apparatus according to
30. The apparatus according to
31. The apparatus according to
32. The apparatus according to
33. The apparatus according to
34. The apparatus according to
0. 35. The apparatus according to
0. 36. The apparatus according to
37. The apparatus according to claim 36 28 wherein element (d) is further defined as means for obtaining a frequency domain power spectrum of the emg signals signal to derive the measure of emg activity in the patient.
38. The apparatus according to claim 35 37 wherein element (c) is further defined as a sensor for obtaining emg signals resulting from the muscle activity of the patient and element (d) is further defined as means for deriving the complexity characteristics of the EEG signal data over a frequency spectrum incorporating the EEG signals signal data and emg signals signal for use with a derived measure of EEG signal data complexity characteristics to determine the hypnotic level of the patient.
39. The apparatus according to
40. The apparatus according to
41. The apparatus according to
42. The apparatus according to
43. The apparatus according to
44. The apparatus according to
45. The apparatus according to
46. The apparatus according to
47. The apparatus according to
48. The apparatus according to
49. The apparatus according to
50. The apparatus according to
51. The apparatus according to claim 50 28 further including storage means for storing information relating to one or more of the patient, the hypnotic drug, a medical procedure, and a physician for use in controlling the administration of the hypnotic drug to the patient.
52. The apparatus according to
53. The apparatus according to
54. The apparatus according to
|
The present application claims the priority of U.S. provisional application 60/291,873, filed May 18, 2001.
The present invention is directed to a method and apparatus for controlling the administration of an hypnotic drug in “closed loop” fashion.
An hypnotic drug may comprise an anesthetic agent and the hypnotic state induced in a patient by the administration of such a drug in one of anesthetization. An hypnotic drug typically acts on the brain to produce a lessening or loss of consciousness in the patient. The extent to which the patient is anesthetized is often termed the “hypnotic level” or “depth of anesthesia.” In the present invention, the existing hypnotic level, or depth of anesthesia, in the patient is sensed and used to control the hypnotic drug administration to the patient in the manner of a closed loop, or feedback, regulator to achieve and maintain a desired level in the patient.
More particularly, the present invention employs the complexity of electroencephalographic (EEG) data obtained from the patient as a sensed indication of the hypnotic level of the patient for use in controlling hypnotic drug administration. The use of such an indication provides closed loop control of drug administration that is based on an accurate assessment of the hypnotic condition of the patient and one that is highly responsive to changes in that condition. Such an indication can be made rapidly responsive to changes in the hypnotic condition of the patient.
Hypnotic drugs, or anesthetic agents, are administered by inhalation or intravenously. When administration is by inhalation, the anesthetic agent comprises a volatile liquid that is vaporized in a vaporizer. The vaporized anesthetic agent is entrained in breathing gases for the patient. The concentration of the anesthetic agent supplied by the vaporizer is determined by the anesthesiologist by manipulating appropriate controls on the vaporizer. The concentration of anesthetic agent in the lungs of the patient may be measured by measuring the amount of anesthetic agent contained in the breathing gases exhaled by the patient at the end of the exhalation phase of the respiratory cycle, i.e. the end tidal concentration (ETconc). Typical inhaled anesthetic agents are sevoflurane, enflurane, and desflurane, among others.
In a simple form, intravenous administration of an hypnotic drug may employ a syringe that injects the drug into a vein of the patient. For extended administration, a motor driven syringe or a motor driven infusion pump may be employed. A commonly used, intravenously administered, anesthetic agent is propofol.
In addition to hypnosis, high quality anesthesia must also consider loss of sensation (analgesia), muscle relaxation, suppression of the autonomous nervous system, and blockage of the neuro muscular function. This may require administration of a number of different drugs via the same or different routes. Further, different hypnotic drugs and/or different administration routes may be used at different stages of an anesthetization or a medical procedure. For example, hypnosis may be introduced by an intravenously administered drug and maintained by an inhaled drug.
In the process by which a drug, including a hypnotic drug, takes its effect in the body, two aspects are important: pharmacokinetics and pharmacodynamics. 24 26 also contains one or more computational elements, such as a microprocessor, that performs artifact detection and removal and determines the spectral entropy or other characterization of the amount of complexity or disorder in the EEG signal obtained from electrodes 20, as well as spectral power data derived from the EMG signal data obtained from the electrodes, thereby to provide EEG signal data.
The output of EEG complexity determination unit 26 comprises a diagnostic index or other value indicative of the complexity or disorder of the EEG signal data. As noted above, it is deemed preferable for reasons of reducing response times, particularly in sensing the emergence of the patient from the hypnotic state, to incorporate data from EMG signals in such a diagnostic index or value. It may also be advantageous to provide more than one index. For example, indices in which signal complexities have has been computed over different frequency ranges may be used. The output from EEG complexity determination unit is provided to a further input of control unit 16 as shown in
In a simple embodiment of the invention shown in
The hypnotic level existing in patient 12, as ascertained by EEG complexity determination unit 26, is driven toward that corresponding to the input signal from input device 18 by the action of the control loop in control 10 in the well known manner of a closed loop or feedback regulator. The polarity of the reference and feedback inputs to comparator 26 28 are shown in
As shown in
Also as shown in
As further shown in
In the embodiment of the invention schematically shown in
Pharmacokinetic model 52 allows the hypnotic drug to be administered in such a way that its relative concentration in a given compartment, i.e. the brain, can be maintained generally stable, or constant at that which produces the desired hypnotic level. This stability brings a major advantage for both the patient and the anesthesiologist since once an efficient level of drug effect has been reached, the drug level, and hence the hypnotic level will remain constant, thereby to avoid changes in the patient condition, such as regaining consciousness. However, since an hypnotic drug's real effect cannot be fully predicted for a given patient due to pharmacogenetics and because of the variability among individuals of pharmacokinetics models, the use of pharmacodynamic model 54, in addition to pharmacokinetic model 52 and the determination of EEG signal data complexity by unit 26 allows for both the determination of the appropriate effect-site concentration, i.e. the concentration to achieve a given hypnotic level and hence EEG signal data complexity level, as well as a steady state drug level. Where needed for both the models, the “effect” of the hypnotic drug can be measured by evaluating the complexity of the EEG signal data, particularly that originating from the cerebral portion of the EEG signal data.
Also, as shown in
Programmed data in source 56 may also include timing data. This data may be used by control unit 16b to establish a stable, set complexity level for the EEG data signal, and hence hypnotic level in patient 12, for a predetermined period of time. Or, the programmed data may be such that the anesthesiologist could operate program data source 58 56 so that control 10 is operated in a manner to wake the patient after a preset time as for example, by setting up a “wake-up after ten minutes” routine in source 56. Responsive to inputs provided from data source 56, control logic 30a would then establish the required drug administration rates and timing for anesthetic delivery unit 14 to patient 12 to obtain this effect and timing. An analogous procedure could be carried out with respect to the administration of the hypnotic drug to induce unconsciousness, i.e. loss of consciousness in patient 12 at a point in time in the future. Such features are advantageous for cost savings in terms of operating room usage times, amounts of drug used, and the like.
The transfer function generator 50, as well as models 52, 54, may be supplied with information from a database storage device 58. Such a storage device will typically retain reusable data, such as standard data or stored patient data inputted to the storage device or inputted, or developed by control 10. This will enable patient data obtained during a prior anesthetization to be reused should the patient require a subsequent anesthetization with the same drug. If desired, transfer function generator 58 50 may also store information of the type described above in connection with source 56, such as patient type, nature of the surgery, surgical intensity, patterns, drug interaction, etc.
Also, control 10 can record a time series of measured and computed patient information to compute, after enough data is recorded, a patient's specific profile that, thereafter, can be used to predict the behavior of the patient for any particular change of drug delivery rate, as by use of models 52 and 54.
It will be appreciated that, for safety reasons, the control will include appropriate means to allow the anesthesiologist to manually control the delivery of the hypnotic agent, by operation of an input device, by direct intervention at the anesthetic delivery unit, or in same other effective manner.
It is recognized that other equivalents, alternatives, and modifications aside from those expressly stated, are possible and within the scope of the appended claims.
Viertio-Oja, Hanna E., Cohen-Laroque, Emmanuel-S
Patent | Priority | Assignee | Title |
10149938, | Jun 20 2011 | SALZAR, RICHARD H ; MURPHY, WILLIAM H , JR | Distributed medication delivery method having autonomous delivery device |
10537677, | Jan 15 2009 | MEDSTEER | System for controlling injectors of anaesthetics or sedatives with a view to inducing anaesthesia or sedation |
10556063, | Jun 20 2011 | SALZAR, RICHARD H ; MURPHY, WILLIAM H , JR | Distributed medication delivery using autonomous delivery device |
10702208, | Mar 31 2015 | CERENION OY | Apparatus and method for electroencephalographic examination |
7920914, | Apr 12 2007 | Yuan Ze University | Method for monitoring the depth of anesthesia |
8864702, | Jan 15 2009 | MEDSTEER | System for controlling means for injection of anesthetics or sedatives |
9089642, | Jun 20 2011 | SALZAR, RICHARD H ; MURPHY, WILLIAM H , JR | Distributed medication delivery system and method having autonomous delivery devices |
9750430, | Apr 27 2011 | General Electric Company | Methods of intravenous drug monitoring |
9849241, | Apr 24 2013 | Fresenius Kabi Deutschland GmbH | Method of operating a control device for controlling an infusion device |
Patent | Priority | Assignee | Title |
2690178, | |||
4417590, | Jun 09 1978 | Beckman Instruments, Inc. | Electroencephalograph |
4421122, | May 15 1981 | CHILDREN S MEDICAL CENTER CORPORATION, THE | Brain electrical activity mapping |
4533346, | Jun 26 1979 | PharmaControl Corporation | System for automatic feedback-controlled administration of drugs |
4705049, | Aug 04 1986 | Intraoperative monitoring or EP evaluation system utilizing an automatic adaptive self-optimizing digital comb filter | |
4753246, | Mar 28 1986 | Regents of the University of California, The | EEG spatial filter and method |
4907597, | Oct 09 1987 | ASPECT MEDICAL SYSTEMS, INC | Cerebral biopotential analysis system and method |
5010891, | Oct 09 1987 | ASPECT MEDICAL SYSTEMS, INC | Cerebral biopotential analysis system and method |
5109862, | Mar 19 1990 | Del Mar Avionics | Method and apparatus for spectral analysis of electrocardiographic signals |
5320109, | Oct 25 1991 | Nellcor Puritan Bennett LLC | Cerebral biopotential analysis system and method |
5458117, | Oct 25 1991 | Nellcor Puritan Bennett LLC | Cerebral biopotential analysis system and method |
5474082, | Jan 06 1993 | BRAIN ACTUATED TECHNOLOGIES, INC | Brain-body actuated system |
5566678, | Sep 10 1993 | Cadwell Industries, Inc. | Digital EEG noise synthesizer |
5579774, | Mar 07 1994 | NOVUS MONITORING LIMITED | Method and apparatus for monitoring local cerebral physiology |
5769793, | Sep 08 1989 | PINCUS, STEPHEN M | System to determine a relative amount of patternness |
5816247, | Jun 13 1995 | RDM CONSULTANTS LTD | Monitoring an EEG |
5846208, | Sep 04 1996 | Siemens Aktiengesellschaft | Method and apparatus for the evaluation of EEG data |
5857978, | Mar 20 1996 | Lockheed Martin Energy Systems, Inc. | Epileptic seizure prediction by non-linear methods |
5995868, | Jan 23 1996 | University of Kansas | System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject |
6016444, | Dec 10 1997 | New York University | Automatic control of anesthesia using quantitative EEG |
6061593, | Oct 27 1997 | NeuroPace, Inc | EEG d-c voltage shift as a means for detecting the onset of a neurological event |
6067467, | Feb 07 1994 | New York University | EEG operative and post-operative patient monitoring method |
6117066, | Dec 04 1992 | Somatics, Inc. | Prevention of seizure arising from medical magnetoictal non-convulsive stimulation therapy |
6128094, | Jul 08 1998 | HEWLETT-PACKARD DEVELOPMENT COMPANY, L P | Printer having processor with instruction cache and compressed program store |
6138668, | Jul 02 1991 | Novartis Pharma AG | Method and device for delivering aerosolized medicaments |
6594524, | Dec 12 2000 | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE | Adaptive method and apparatus for forecasting and controlling neurological disturbances under a multi-level control |
6678548, | Oct 20 2000 | The Trustees of the University of Pennsylvania | Unified probabilistic framework for predicting and detecting seizure onsets in the brain and multitherapeutic device |
6731975, | Oct 16 2000 | Instrumentarium Corp | Method and apparatus for determining the cerebral state of a patient with fast response |
20020061540, | |||
GB2113843, | |||
GB2113846, | |||
WO232305, | |||
WO9734648, | |||
WO9810701, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Dec 31 2004 | Instrumentarium Corp | GE Healthcare Finland Oy | DEMERGER PLAN | 023548 | /0841 | |
Sep 21 2005 | GE Healthcare Finland Oy | (assignment on the face of the patent) | / |
Date | Maintenance Fee Events |
Apr 07 2011 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
Apr 07 2015 | M1553: Payment of Maintenance Fee, 12th Year, Large Entity. |
Date | Maintenance Schedule |
Apr 27 2013 | 4 years fee payment window open |
Oct 27 2013 | 6 months grace period start (w surcharge) |
Apr 27 2014 | patent expiry (for year 4) |
Apr 27 2016 | 2 years to revive unintentionally abandoned end. (for year 4) |
Apr 27 2017 | 8 years fee payment window open |
Oct 27 2017 | 6 months grace period start (w surcharge) |
Apr 27 2018 | patent expiry (for year 8) |
Apr 27 2020 | 2 years to revive unintentionally abandoned end. (for year 8) |
Apr 27 2021 | 12 years fee payment window open |
Oct 27 2021 | 6 months grace period start (w surcharge) |
Apr 27 2022 | patent expiry (for year 12) |
Apr 27 2024 | 2 years to revive unintentionally abandoned end. (for year 12) |